Market Research Report
Digital Therapeutics Market by Application, Product, and Sales Channel : Global Opportunity Analysis and Industry Forecast, 2017 - 2025
|Published by||Allied Market Research||Product code||724055|
|Published||Content info||225 Pages
Delivery time: 2-3 business days
|Digital Therapeutics Market by Application, Product, and Sales Channel : Global Opportunity Analysis and Industry Forecast, 2017 - 2025|
|Published: September 1, 2018||Content info: 225 Pages||
Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Diseases (CVD), Central Nervous System (CNS) Disease, Gastrointestinal Disorders (GID), Respiratory Diseases, Smoking Cessation, and Others), Product (Software and Devices), and Sales Channel (Business-to-business [B2B] and Business-to-consumers [B2C]): Global Opportunity Analysis and Industry Forecast, 2017 - 2025 .
The global digital therapeutics market was valued at $1,751 million in 2017 and is expected to reach $7,833 million by 2025, registering a CAGR of 20.5% during the forecast period. Digital therapeutics is a type of treatment option, which utilizes online health technologies and digital devices to treat numerous medical conditions and help maintain health discipline.
Increase in adoption of smartphones & tablets coupled with rise in utilization of healthcare apps is the major factor that drives the growth of the global digital therapeutics market. In addition, increasing need to control healthcare costs supplements the market growth. However, lack of awareness regarding the availability of smartphone applications, especially in the developing countries, acts a major deterrent to the market growth. Conversely, high growth potential in the developing markets is expected to offer significant opportunities for the players operating in this market.
The global digital therapeutics market is segmented into application, product, sales channel, and region. Based on application, the market is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. On the basis of product, it is classified into software and devices. By sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, the business - to - business (B2B) segment is categorized into employers, healthcare providers, and others. Depending on business-to-consumers, the market is fragmented into patients and caregivers. Regionally, it is analyzed across North America, Europe, Asia - Pacific, and LAMEA.